Ticker

Oruka Therapeutics (NASDAQ: ORKA - Get Free Report)'s stock had its "buy" rating restated by analysts at BTIG Research in a research report issued on Monday, Benzinga reports. They currently have a $151.00 price target on the stock. BTIG Research's price objective would indicate a potential upside of 98.59% from the stock's current price. Several other

Oruka Therapeutics is positioned as a leader in ultra-long-acting injectable treatments for psoriasis, with ORKA-001 showing class-leading efficacy. ORKA-001's PASI 100 and PASI 90 rates at Week 28 reinforce its durability, while a replicated response in the crossover cohort strengthens confidence in trial results. ORKA's $1.1B cash balance, exclusive Hypercon technology license, and pipeline breadth provide funding…

Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.

Oruka Therapeutics Inc. (NASDAQ:ORKA) on Wednesday reported positive week 28 outcomes from its Phase 2a clinical trial evaluating ORKA-001 for moderate-to-severe plaque psoriasis.

PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ORKA-001 maintained a favorable safety and tolerability profile through Week 28 52-week EVERLAST-A data for all patients expected in December 2026 16-week EVERLAST-B data expected in 4Q 2026 MENLO PARK, Calif., Sept.…